אגיסטן וי % 2 קרם וגינלי ישראל - עברית - Ministry of Health

אגיסטן וי % 2 קרם וגינלי

padagis israel pharmaceuticals ltd, israel - clotrimazole - קרם וגינלי - clotrimazole 2 % - clotrimazole - clotrimazole - broad spectrum antimycotic with fungicidal action

סינולוקס LC וטרינרי ישראל - עברית - Ministry of Health

סינולוקס lc וטרינרי

pfizer pharmaceuticals israel ltd - amoxicillin as trihydrate 200 mg/dose; clavulanic acid as potassium 55 mg/dose - suspension for injection - combinations - for the treatment of bovine mastitis in lactating cows. it has a broad spectrum of bactericidal activity against bacteria which are sensitive to synulox isolated from the bovine udder.

רוספין 1 גר' תוך שרירי ישראל - עברית - Ministry of Health

רוספין 1 גר' תוך שרירי

roche pharmaceuticals (israel) ltd - ceftriaxone as sodium 1000 mg/vial - powder and solvent for solution for injection - ceftriaxone - long-acting, broad spectrum cephalosporin, for the treatment of infections caused by susceptible organisms.

צפטריאקסון - פרזניוס ישראל - עברית - Ministry of Health

צפטריאקסון - פרזניוס

neopharm (israel) 1996 ltd - ceftriaxone as sodium - אבקה להמסה להזרקה\אינפוזיה - ceftriaxone as sodium 1000 mg/vial - ceftriaxone - ceftriaxone - long-acting, broad spectrum cephalosporin, for the treatment of infections caused by susceptible organisms.

ציפרודקס 250 ישראל - עברית - Ministry of Health

ציפרודקס 250

dexcel ltd, israel - ciprofloxacin as hydrochloride - טבליה - ciprofloxacin as hydrochloride 250 mg - ciprofloxacin - ciprofloxacin - broad spectrum antibiotic for infections caused by ciprofloxacin sensitive pathogens: invasive infections of the external ear. treatment of acute pulmonary exacerbation of cystic fibrosis associated with p. aeruginosa infections in pediatric patients aged 5-17 years.

ציפרודקס 500 ישראל - עברית - Ministry of Health

ציפרודקס 500

dexcel ltd, israel - ciprofloxacin as hydrochloride - קפליות - ciprofloxacin as hydrochloride 500 mg - ciprofloxacin - ciprofloxacin - broad spectrum antibiotic for infections caused by ciprofloxacin sensitive pathogens: invasive infections of the external ear. treatment of acute pulmonary exacerbation of cystic fibrosis associated with p. aeruginosa infections in pediatric patients aged 5-17 years.

ציפרודקס 750 ישראל - עברית - Ministry of Health

ציפרודקס 750

dexcel ltd, israel - ciprofloxacin as hydrochloride - קפליות - ciprofloxacin as hydrochloride 750 mg - ciprofloxacin - ciprofloxacin - broad spectrum antibiotic for infections caused by ciprofloxacin sensitive pathogens: invasive infections of the external ear. treatment of acute pulmonary exacerbation of cystic fibrosis associated with p. aeruginosa infections in pediatric patients aged 5-17 years.

ציפרופלוקסצין טבע 500 מג ישראל - עברית - Ministry of Health

ציפרופלוקסצין טבע 500 מג

teva israel ltd - ciprofloxacin as hydrochloride - טבליה - ciprofloxacin as hydrochloride 500 mg - ciprofloxacin - ciprofloxacin - broad spectrum antibiotic for infections caused by ciprofloxacin sensitive pathogens: invasive infections of the external ear. treatment of acute pulmonary exacerbation of cystic fibrosis associated with p. aeruginosa infections in pediatric patients aged 5-17 years.

ג'ירופלוקס ישראל - עברית - Ministry of Health

ג'ירופלוקס

bioavenir ltd, israel - ciprofloxacin - תמיסה לאינפוזיה - ciprofloxacin 200 mg / 100 ml - ciprofloxacin - ciprofloxacin - broad spectrum antibiotic for infections caused by ciprofloxacin sensitive pathogens: treatment of acute pulmonary exacerbation of cystic fibrosis associated with p.aeroginosa infections in pediatric patients aged 5-17 years.

אפירוביצין טבע ® 2 מ"ג/מ"ל ישראל - עברית - Ministry of Health

אפירוביצין טבע ® 2 מ"ג/מ"ל

salomon,levin & elstein ltd - epirubicin hydrochloride 2 mg / 1 ml - solution for injection / infusion - epirubicin - for the treatment of wide spectrum of neoplastic diseases, including:- breast carcinoma- lung carcinoma - high doses- ovarian carcinoma- gastric carcinomas- soft tissue sarcoma- i.v. administration for the treatment of advanced bladder carcinoma- intravesical administration of epirubicin has been found to be beneficial in the treatment of superficial bladder carcinomas and in the prophylaxis of recurrences after transurethral resection.